Where does Sapience Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sapience Therapeutics, Inc. ranks #8,471 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sapience Therapeutics, Inc. hold?

Sapience Therapeutics, Inc. holds 38 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Sapience Therapeutics, Inc.'s Innovation Score?

Sapience Therapeutics, Inc. has an Innovation Score of 46.3 out of 100 (top 21% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Sapience Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Sapience Therapeutics, Inc.'s recent grant velocity is +18% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Sapience Therapeutics, Inc.'s patents?

Sapience Therapeutics, Inc.'s patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sapience Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sapience Therapeutics, Inc.

Q: What technology areas does Sapience Therapeutics, Inc. focus on?

Sapience Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 36 patents. Grants appear in 12 CPC subclasses total.

USPTO PatentsView assignee record - 38 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sapience ranks #8,471 of 50,000 tracked US assignees by granted-patent volume, with 38 patents across 12 technology areas.

#8,471
of 50,000 US assignees by volume: Top 21%
by Innovation Score (46.3/100): 17.2
avg claims per patent: +18%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8471 · US Corporation #8,471 · 38 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 38 grants
UPPER-Q #8,471/50,000
PHOTO-FINISH Sarcos
CPC-FOCUS C12N · 12 areas
INNOV-PAR 46.3/100
CLAIMS-RICH 17.2 claims/avg
TYPE-USCORP US Corporation
VEL-UP +18% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sarcos Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Canrig Robotic AS · near

46
Safran Cabin · near

46
Sapience Therapeutics · this assignee

46
Schroeder Industries · near

46
Tigo Energy · near

46
3D Lighting Innovati… · lowest

7

What this shows Sapience Therapeutics, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-RICH, TYPE-USCORP, VEL-UP, BOOK-FULL. Volume places it #8,471 of 50,000; Innovation Score 46.3/100 sits in the top 21% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Sarcos Corp. (±0 grants).

Portfolio overview

Sapience Therapeutics, Inc. has been granted 38 US utility patents between 2015 and 2025, placing Sapience Therapeutics, Inc. at #8,471 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.2 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Sapience Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Sapience sits between SDL Inc. (38 patents, rank #8,474) and Siluria Technologies, Inc. (38 patents, rank #8,482) - the closest US assignees by grant volume. The composite Innovation Score of 46.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 20 grants, compared with 17 in the 2015–2019 window, a +18% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Sapience Therapeutics, Inc.'s 17.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 12 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

SDL

38
Shenzhen Hithium…

38
Suzhou Institute…

38
Sync-rx

38
Sarcos

38
Secureauth

38
Silicon Integrate…

38
Siluria

38
Sapience Therapeu… ◀

38

What this shows Sapience holds 38 patents at rank #8,478, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sapience

By rank, the assignees closest to #8,478 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Sapience's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sapience, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Canrig Robotic Technologies AS 46 Safran Cabin Inc. 46 Schroeder Industries, Llc 46 Tigo Energy, Inc. 46

Sapience's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sapience Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	13.2%
2016	3	7.9%
2017	5	13.2%
2019	4	10.5%
2020	2	5.3%
2021	3	7.9%
2022	4	10.5%
2023	4	10.5%
2024	7	18.4%
2025partial year	1	2.6%

Which technologies does Sapience Therapeutics, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 36

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 31

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 31

C12Y - ENZYMES 15

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 14

C07K - PEPTIDES 4

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 3

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

Y10S - TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS 1

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 1

Top 12 of 12 technology areas

Where it ranks

Overall rank by patents

#8,471

of 50,000 tracked assignees

Innovation Score

46.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.